FORM OF SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 31st, 2022 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 31st, 2022 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of March 29, 2022, between Aravive, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
ARAVIVE, INC., Issuer AND [TRUSTEE], TrusteeIndenture • June 20th, 2023 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 20th, 2023 Company Industry JurisdictionWHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
•] Shares VERSARTIS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • January 20th, 2015 • Versartis, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 20th, 2015 Company Industry Jurisdiction
VERSARTIS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OFPreferred Stock Warrant Agreement • August 7th, 2017 • Versartis, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 7th, 2017 Company Industry JurisdictionTHIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between VERSARTIS, INC., a Delaware corporation (the “Company”) and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
VERSARTIS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OFCommon Stock Warrant Agreement • August 7th, 2017 • Versartis, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 7th, 2017 Company Industry JurisdictionTHIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VERSARTIS, INC., a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
VERSARTIS, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20Warrant Agreement • August 7th, 2017 • Versartis, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 7th, 2017 Company Industry JurisdictionThis DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between VERSARTIS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
VERSARTIS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • August 10th, 2017 • Versartis, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 10th, 2017 Company Industry JurisdictionVersartis, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
VERSARTIS, INC. Common Stock, Par Value $0.0001 Per Share UNDERWRITING AGREEMENTUnderwriting Agreement • September 29th, 2016 • Versartis, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 29th, 2016 Company Industry Jurisdiction
FORM OF SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 31st, 2022 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 31st, 2022 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of March 29, 2022, between Aravive, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
3,333,334 Shares ARAVIVE, INC. Common Stock PURCHASE AGREEMENTPurchase Agreement • November 27th, 2019 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 27th, 2019 Company Industry JurisdictionAravive, Inc., a Delaware corporation (the “Company”), proposes to sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 3,333,334 shares (the “Firm Shares”) of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company. The Firm Shares consist of 3,333,334 authorized but unissued shares of Common Stock to be issued and sold by the Company. The Company has also granted to the several Underwriters an option to purchase up to 500,000 additional shares of Common Stock, on the terms and for the purposes set forth in Section 3 hereof (the “Option Shares”). The Firm Shares and any Option Shares purchased pursuant to this Agreement are herein collectively called the “Shares.”
VERSARTIS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20Debt Securities Warrant Agreement • November 6th, 2015 • Versartis, Inc. • Pharmaceutical preparations • New York
Contract Type FiledNovember 6th, 2015 Company Industry JurisdictionDEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between VERSARTIS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
ARAVIVE, INC. EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • March 26th, 2019 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMarch 26th, 2019 Company Industry JurisdictionAs further set forth in this agreement (this “Agreement”), Aravive, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Piper Jaffray & Co. (the “Agent”), as sales agent, the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (such shares of Common Stock to be sold pursuant to this Agreement, the “Shares”) on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agent shall have no obligation in connection with such compliance.
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: VERSARTIS, INC., a Delaware corporation; VELO MERGER SUB, INC. a Delaware corporation; and ARAVIVE BIOLOGICS, INC., a Delaware corporation Dated as of June 3, 2018Merger Agreement • June 4th, 2018 • Versartis, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJune 4th, 2018 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION (this “Agreement”) is made and entered into as of June 3, 2018, by and among VERSARTIS, INC., a Delaware corporation (“Parent”), VELO MERGER SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and ARAVIVE BIOLOGICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
Office Lease SHOREBREEZE SHOREBREEZE I REDWOOD CITY, CALIFORNIA Between CA- SHOREBREEZE LIMITED PARTNERSHIP, a Delaware limited partnership as Landlord, and VERSARTIS, Inc., a Delaware corporation as TenantOffice Lease • February 18th, 2014 • Versartis, Inc. • Pharmaceutical preparations • California
Contract Type FiledFebruary 18th, 2014 Company Industry JurisdictionThis Office Lease (this “Lease”), dated as of the date set forth in Section 1.1. is made by and between CA-SHOREBREEZE LIMITED PARTNERSHIP, a Delaware limited partnership (“Landlord”), and VERSARTIS, INC, a Delaware corporation (“Tenant”). The following exhibits are incorporated herein and made a part hereof Exhibit A (Outline of Premises); Exhibit B (Work Letter); Exhibit B-1 (Space Plan); Exhibit C (Form of Confirmation Letter); Exhibit D (Rules and Regulations); Exhibit E (Judicial Reference); and Exhibit F (Additional Provisions).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 28th, 2022 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 28th, 2022 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of October 24, 2022, by and between Aravive, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
VERSARTIS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 6th, 2014 • Versartis, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 6th, 2014 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (“Agreement”) is effective as of , 2014, by and between VERSARTIS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
RUGA CORPORATION INDEMNIFICATION AGREEMENTIndemnification Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 3rd, 2018 Company Industry JurisdictionThis Indemnification Agreement (the “Agreement”) is made as of October 17, 2016, by and between Ruga Corporation, a Delaware corporation (the “Company”), and Vinay Shah (“Indemnitee”).
River Oaks Tower Houston, Texas 77098Employment Agreement • March 16th, 2021 • Aravive, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMarch 16th, 2021 Company Industry JurisdictionAravive, Inc. (the “Company”) is pleased to continue your employment as Chief Medical Officer of the Company and its subsidiaries on the following terms:
TECHNOLOGY TRANSFER AND CLINICAL SUPPLY AGREEMENTTechnology Transfer and Clinical Supply Agreement • March 19th, 2014 • Versartis, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 19th, 2014 Company Industry[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
SUPPORT AGREEMENTSupport Agreement • June 4th, 2018 • Versartis, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJune 4th, 2018 Company Industry JurisdictionThis SUPPORT AGREEMENT (this “Agreement”), is made as of June 3, 2018, by and between Versartis, Inc., a Delaware corporation (“Versartis”) and the Person set forth on Schedule A hereto (the “Stockholder”).
VERSARTIS, INC. FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT February 14, 2014Investors Rights Agreement • February 18th, 2014 • Versartis, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 18th, 2014 Company Industry JurisdictionTHIS FOURTH AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (the “Agreement”) is made as of the 14th day of February, 2014, by and among Versartis, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor.”
INVESTMENT AGREEMENTInvestment Agreement • April 9th, 2020 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledApril 9th, 2020 Company Industry JurisdictionTHIS INVESTMENT AGREEMENT (this “Agreement”) is made and entered into at 3:30 p.m. on April 6, 2020, by and among Eshelman Ventures, LLC, a North Carolina limited liability company (the “Investor”), Aravive, Inc., a Delaware corporation (the “Company”), and, solely for purposes of Article IV and Article V, Fredric N. Eshelman, Pharm.D. (the “Incoming Chairman”).
MASTER MANUFACTURING SERVICES AGREEMENTMaster Manufacturing Services Agreement • August 24th, 2018 • Versartis, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 24th, 2018 Company Industry JurisdictionTHIS MASTER MANUFACTURING SERVICES AGREEMENT (this “Agreement”) is entered into as of July 11, 2016 (the “Effective Date”), by and between WUXI BIOLOGICS (HONG KONG) LIMITED having a principal place of business at 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China 200131 (“CMO”), and ARAVIVE BIOLOGICS, INC., having a principal place of business at 909 Fannin, Suite 2100, Houston, Texas 77010 (“Client”). CMO and Client are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 24th, 2018 • Versartis, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 24th, 2018 Company Industry JurisdictionThis Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Ruga Corporation, (“RUGA”), a corporation having a principal place of business at 550 Hamilton Avenue, Suite 220, Palo Alto CA 94301, is effective on the 25th day of January, 2012 (“Effective Date”).
Consulting AgreementConsulting Agreement • June 3rd, 2022 • Aravive, Inc. • Pharmaceutical preparations • California
Contract Type FiledJune 3rd, 2022 Company Industry JurisdictionThis Professional Services Agreement (this “Agreement”), dated June 2, 2022 (the “Effective Date”), is by and between Aravive, Inc. (“Company”), and Vinay Shah (“Service Provider”).
EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • September 4th, 2020 • Aravive, Inc. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 4th, 2020 Company Industry JurisdictionAs further set forth in this agreement (this “Agreement”), Aravive, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. and Cantor Fitzgerald & Co. (each an “Agent”, and together, the “Agents”), as sales agents, the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”) (such Common Stock to be sold pursuant to this Agreement, the “Shares”), on terms set forth herein. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in Section 2 of this Agreement on the number of Shares issued and sold under this Agreement shall be the sole responsibility of the Company, and the Agents shall have no obligation in connection with such compliance.
LICENSE AGREEMENTLicense Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 3rd, 2018 Company IndustryThis license agreement (“Agreement”), effective as of December 1, 2017 (“Effective Date”) is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Suite 3701-10, 37F, Jardine Hse, 1 Connaught Place, Central Hong Kong (“WuXi Biologics”) and Aravive Biologics, Inc., having its principal place of business at 1221 McKinney Street, Suite 3200, Houston, Texas 77010 (“Licensee”).
Re:Separation and Consulting AgreementSeparation and Consulting Agreement • August 5th, 2015 • Versartis, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 5th, 2015 Company Industry JurisdictionThis letter agreement (the “Agreement”) sets forth the terms of your separation and transition from Versartis, Inc. (“Versartis” or the “Company”).
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 3rd, 2018 • Versartis, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 3rd, 2018 Company Industry JurisdictionThis AMENDMENT (the Amendment”) dated as of July 26, 2012 to the EXCLUSIVE LICENSE AGREEMENT (the “License Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and RUGA CORPORATION (“RUGA”), a corporation having a principal place of business at 550 Hamilton Avenue, Suite 220, Palo Alto CA 94301, effective as of January 25, 2012.
AMENDMENT NO. 1 TO SECOND AMENDED AND RESTATED LICENSING AGREEMENTLicensing Agreement • February 18th, 2014 • Versartis, Inc. • Pharmaceutical preparations • California
Contract Type FiledFebruary 18th, 2014 Company Industry JurisdictionThis Amendment No. 1 (“Amendment No. 1”) to the Second Amended and Restated Licensing Agreement dated December 30, 2010 (the “Agreement”) by and between Amunix Operating, Inc. (“Licensor”) and Versartis, Inc. (“Licensee”).
AMUNIX OPERATING INC. 500 Ellis Street Mountain View, CA 94043License Agreement • August 7th, 2017 • Versartis, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 7th, 2017 Company Industry JurisdictionThis Letter Agreement (“Letter Agreement”) is made effective as of March 22, 2016 (“Amendment Effective Date”) by and between Versartis, Inc., a Delaware corporation (“Licensee”) and Amunix Operating, Inc., a Delaware corporation (“Licensor”). This Letter Agreement makes reference to that certain Second Amended and Restated Licensing Agreement between Amunix and Versartis, dated December 30, 2010, as amended by that certain Amendment No. 1 and Amendment No. 2 (collectively, the “License Agreement”).
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • November 10th, 2020 • Aravive, Inc. • Pharmaceutical preparations • England and Wales
Contract Type FiledNovember 10th, 2020 Company Industry JurisdictionThis Collaboration and License Agreement (the “Agreement”) is entered into as of November 6, 2020 (the “Effective Date”) by and between Aravive, Inc., a corporation organized and existing under the laws of Delaware and having a place of business at 3730 Kirby Drive, Suite 1200, Houston, Texas 77098 USA (“Aravive”), and 3D Medicines Inc., a corporation organized and existing under the laws of the Cayman Islands and having a place of business at Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands (“3D Medicines”). Aravive and 3D Medicines are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractCommercial Supply Agreement • March 10th, 2017 • Versartis, Inc. • Pharmaceutical preparations
Contract Type FiledMarch 10th, 2017 Company Industry[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Consulting AgreementConsulting Agreement • January 9th, 2020 • Aravive, Inc. • Pharmaceutical preparations • Texas
Contract Type FiledJanuary 9th, 2020 Company Industry JurisdictionThis Professional Services Agreement (this “Agreement”), dated January 9, 2020 (the “Effective Date”), is by and between Aravive, Inc. (“Company”), and Jay Shepard (“Service Provider”).
CONFIDENTIAL SEPARATION AGREEMENT AND RELEASESeparation Agreement • January 17th, 2024 • Aravive, Inc. • Pharmaceutical preparations
Contract Type FiledJanuary 17th, 2024 Company IndustryThis Confidential Separation Agreement and Release (the “Agreement”) is entered into between Aravive, Inc. and its related entities (the “Company”) and Gail McIntyre (the “Employee”), in connection with the end of the employment relationship between Employee and the Company, to assist Employee in transitioning to new employment, and to release any and all claims or potential claims Employee has or may have against the Company. Accordingly, in exchange for the consideration and mutual promises set forth herein, the receipt and sufficiency of which are hereby acknowledged, the Company and the Employee (the “Parties”), intending to be legally bound, do hereby agree and promise as follows: